Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials.

What the trial testedas reported · 4,339 people · 2024

Not counted

−54%−72% to −25%

Bigger than 8 in 10 on the map

As reported

RR 0.46, 95% CI 0.28–0.75

the abstract, start to end

… defined as BS ≤ 70 mg/dL (RR 0.46, 95% CI (0.28, 0.75)).

← favours treatmentfavours comparator →

could be chance

Blood pressure

RR 0.460.28–0.75

GIP/GLP-1 & amylin agonistsInsulinBlood pressure

1 / 3

2024

2025

2026

this paperpooled itcites it